Drugs · Entity Annotation Prototype (beta)

7articles mentioning drugs

43drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: αPD-1 ×

αPD-1

This drug is selected. Its supporting articles are shown below.

αPD-17

Articles mentioning αPD-1

7 articles · page 1 of 1

990 A highly TME-selective αPD-1/αVEGF/IL-2v tri-specific fusion protein demonstrates potent anti-tumor activity beyond αPD-1/αVEGF therapy

jitc · abstract · 2025-11-04 · 21 matching annotations

91.2%

αPD-1 IL-2v

…n TKI-resistant lung cancer bearing humanized mice, compared to αPD-1 or αPD-1/αVEGF bsAbs.Conclusions αPD-1/αVEGF/IL-2v is a highly …

Twenty-four-week anti-PD-1 antibody regimen promoted HBsAg reduction and concurrently enhanced HBV-specific T cell responses in patients with chronic hepatitis B

gutjnl · abstract · 2026-07-08 · 8 matching annotations

89.2%

αPD-1 sintilimab chronic hepatitis B (CHB)CHB

… the most common AEs, and they represented the only severe AEs. αPD-1 add-on therapy induced greater HBsAg reductions (mean decline: …

455 Treg-associated ICOS as a possible biomarker for PD-1 therapy resistance in melanoma patients

jitc · abstract · 2025-11-04 · 7 matching annotations

90.8%

nivolumab ipilimumab αPD-1 University of California Irvine melanoma Chao Family Comprehensive Cancer Center PD-1 immunotherapy

…5784.References Wolchok JD, et al. Final, 10-year outcomes with nivolumab plus ipilimumab in advanced melanoma. New England Journal of Me…

459 Murine breast cancer cell lines with differential responsiveness to immunotherapy

jitc · abstract · 2025-11-04 · 2 matching annotations

90.8%

αCTLA-4 αPD-1 Breast cancer mammary cancer The University of Texas Health San Antonio

…erapy treatment groups, whereas MM001i tumors responded only to αCTLA-4. Both tumor cell lines also triggered robust memory responses. …

54 Development and characterization of cytokine-based classifiers to predict response to immunotherapy using an ex vivo live tumor fragment platform

jitc · abstract · 2025-11-04 · 2 matching annotations

89.0%

αPD-1 αPD-L1 αCTLA-4 Voabil et al.NCT05478538

…equentially on the same tissue in a single well. ICI treatment (αPD-1, αPD-L1 or αPD-1+αCTLA-4) was aligned with the anticipated clin…

693 A novel tri-therapy overcoming immune suppression, immune exhaustion, and low antigen-specific T cell infiltration elicits robust antitumor responses

jitc · abstract · 2025-11-04 · 2 matching annotations

83.7%

anti-PD-1 αPD-1 BRQ Roswell Park American Association of Laboratory Animal Care solid tumors

…fficacy, including immune checkpoint inhibitors (ICIs), such as anti-PD-1.11 To overcome the obstacle of MDSCs, our laboratory developed …

SAMHD1 drives immunosuppression in non-small cell lung cancer by promoting macrophage infiltration and restricting oncolytic adenovirus replication

jitc · abstract · 2026-01-28 · 1 matching annotations

78.7%

oAd-vpx αPD-1 Non-small cell lung cancer NSCLC lung cancer

…+T-cell-dependent antitumor immune response. The combination of oAd-vpx and αPD-1 inhibits tumor growth and enhances sensitivity to ICI…

Browse drugs

αPD-1

Articles mentioning αPD-1

990 A highly TME-selective αPD-1/αVEGF/IL-2v tri-specific fusion protein demonstrates potent anti-tumor activity beyond αPD-1/αVEGF therapy

Twenty-four-week anti-PD-1 antibody regimen promoted HBsAg reduction and concurrently enhanced HBV-specific T cell responses in patients with chronic hepatitis B

455 Treg-associated ICOS as a possible biomarker for PD-1 therapy resistance in melanoma patients

459 Murine breast cancer cell lines with differential responsiveness to immunotherapy

54 Development and characterization of cytokine-based classifiers to predict response to immunotherapy using an ex vivo live tumor fragment platform

693 A novel tri-therapy overcoming immune suppression, immune exhaustion, and low antigen-specific T cell infiltration elicits robust antitumor responses

SAMHD1 drives immunosuppression in non-small cell lung cancer by promoting macrophage infiltration and restricting oncolytic adenovirus replication